Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation [3] [4]
Especially, most of the observational studies reported treatment initiation after more than 50 months
The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, which were generally mild to moderate and tended to improve over time
Key readouts include: TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks , figures that approach outcomes previously associated only with bariatric surgery
Over time, she had gained weight and used the drug to address that
How to buy Semaglutide safely